Premium
An Immunogenomic Investigation of Oral Cavity Squamous Cell Carcinoma in Patients Aged 45 Years and Younger
Author(s) -
Maroun Christopher A.,
Zhu Gangcai,
Fakhry Carole,
Gourin Christine G.,
Seiwert Tanguy Y.,
Vosler Peter S.,
Tan Marietta,
Koch Wayne,
Eisele David W.,
Pardoll Drew M.,
Mandal Rajarsi
Publication year - 2021
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.28674
Subject(s) - medicine , immune system , tigit , young adult , gastroenterology , cancer , immunology , oncology , t cell
Objectives/Hypothesis To investigate differences in the immunogenomic landscape among young patients presenting with oral cavity squamous cell carcinoma (OCSCC). Study Design Retrospective database review. Methods Normalized messenger mRNA expression data were downloaded from The Cancer Genome Atlas (TCGA) database. OCSCC patients were categorized into young and older age groups with a cutoff of 45 years. Human papillomavirus–positive tumors were excluded. Cell fractions, marker expression, and mutational load were compared between age groups using the Wilcoxon rank sum test. Adjustment for multiple comparisons was performed using the Benjamini‐Hochberg method, with a false discovery rate of 0.05. Results Two hundred forty‐five OCSCC tumors were included; 21 (8.6%) were young (37.1 ± 7.5 years) and 224 (91.4%) were older (64.5 ± 10.3 years). There was no significant difference between groups in the fraction of B and T lymphocytes, macrophages, monocytes, natural killers, and dendritic cells. Cytolytic activity score was decreased in young patients (8.33 vs. 18.9, P = .023). Additionally, young patients had significantly lower expression of immunomodulatory markers of immune activation, including PD‐1 ( PDCD1 , P = .003), CTLA4 ( P = .025), TIGIT ( P = .002), GITR ( TNFRSF18 , P = .005), OX40 ( TNFRSF4 , P = .009), LAG‐3 ( P < .001), and TIM‐3 ( HAVCR2 , P = .002). Young patients had a significantly lower number of single nucleotide variant‐derived neoantigens (26.2 vs. 60.6, P < .001). Conclusions OCSCC patients aged 45 years and younger appear to have an attenuated immune response that may be related to a lower frequency of immunogenic mutations. This may contribute to the pathogenesis of these tumors, and ultimately help inform personalized immune‐based therapeutic strategies for young patients with OCSCC. Level of Evidence NA Laryngoscope , 131:304–311, 2021